CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth
2017
The standard of care for ovarian cancer includes initial treatment with chemotherapy. Despite initial efficacy, over 70% of patients develop recurrence; thus, there is a need to identify novel approaches that can improve therapeutic outcomes. We evaluated AMD3100 (Plerixafor), an FDA-approved CXCR4
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
40
References
20
Citations
NaN
KQI